Volumen: 18 # Number : 1
Publication Date : Enero - Abril Year: 2014
Carfilzomib:a second genaration proteasome inhibitor
Authors: Fantl Dorotea
Abstract: Carfilzomib is a second generation proteasome inhibitor being selective and irreversible with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Responses generally occur rapidly. Carfilzomib can partially overcome resistance in bortezomibrefractory patients. Moreover, carfilzomib has the advantage of a favorable safety profile, especially a low incidence of peripheral neuropathy, which is often the dose limiting factor in thalidomide and bortezomib based regimens. The most frequently observed high grade adverse event is cytopenia. However, long term tolerability
is good with no cumulative toxicity. The place of carfilzomib
in the treatment of the advanced and the newly diagnosed
myeloma patient is currently under examination in several ongoing phase 3 clinical trials.
Key words: carfilzomib, drug toxicity,
multiple myeloma,
proteasome inhibitors
Pages : 53-59
|
